Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with relapsed or refractory chronic lymphocytic leukaemia

Ross Salvaris, Stephen Mulligan, Andrea Puig, Marija McGeachie, Stephen Opat

Research output: Contribution to journalArticlepeer-review

Abstract

In Australia, over half of patients with relapsed/refractory chronic lymphocytic leukaemia treated with ibrutinib use concomitant proton pump inhibitors (PPIs). High gastric pH reduces the bioavailability of some Bruton tyrosine kinase inhibitors. There was no difference in duration on ibrutinib with or without concomitant PPI (unadjusted P = 0.61; adjusted hazard ratio: 1.23, 95% confidence interval: 0.75–2.02, P = 0.411). PPI use does not affect ibrutinib treatment persistence.

Original languageEnglish
Pages (from-to)2115-2118
Number of pages4
JournalInternal Medicine Journal
Volume53
Issue number11
Early online date11 Nov 2023
DOIs
Publication statusPublished - Nov 2023

Cite this